Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Feb;48(2):169-72.
doi: 10.1016/0020-7292(94)02271-y.

Intraumbilical oxytocin for management of retained placenta

Affiliations
Clinical Trial

Intraumbilical oxytocin for management of retained placenta

M Makkonen et al. Int J Gynaecol Obstet. 1995 Feb.

Abstract

Objective: The purpose of the study was to investigate the removal of a retained placenta.

Method: Oxytocin was injected into the vein of the umbilical cord. A total of 109 patients with retention of the placenta were randomized into two groups. Active management of the third stage of labor was carried out by giving oxytocin 5 IU intravenously and ergometrine maleate 0.2 mg intramuscularly after delivery of the fetus. Group 1, which comprised 68 patients, was allocated to receive 50 IU oxytocin diluted in 10 ml 0.9% sodium chloride solution, and the 41 patients in group 2 were given 20 ml plasma expander (dextran 70) into the umbilical vein.

Results: Forty-nine cases (72%) in the oxytocin group and 22 cases (54%) in the dextran 70 group required manual removal of the retained placenta. No significant differences were found between group 1 (oxytocin) and group 2 (dextran 70).

Conclusion: Our results indicate that intraumbilical vein injection of oxytocin is not effective for removal of a retained placenta.

PubMed Disclaimer

Publication types

LinkOut - more resources